Moineauworld

Tag: Goldman Sachs

Lilly’s Retatrutide Poised to Reshape | Analysis by Brian Moineau

Posted on by Brian Moineau

TL;DR

  • Retatrutide, Eli Lilly’s triple‑agonist (GLP‑1/GIP/glucagon), produced an average 25% weight loss at week 80 at the 12 mg dose in TRIUMPH‑1 (n=2,339), with a two‑year extension approaching ~30%; knee osteoarthritis pain and obstructive sleep apnea events also improved versus placebo [1].
  • Lilly is positioning retatrutide alongside Zepbound rather than against it, using outcomes that matter to payers—obstructive sleep apnea (FDA‑approved for Zepbound in 2024) and cardiovascular risk (FDA‑approved for Wegovy in 2024)—to expand coverage beyond “weight loss only” claims [4][5].
  • Goldman Sachs models ~$95B in global anti‑obesity drug sales by 2030; even a 10% slice would be multibillion revenue, contingent on Lilly’s $3.5B Pennsylvania manufacturing build and payer adoption following outcomes labels recognized by Medicare Part D [6][8][7].

What the source said

Lilly reported that, in TRIUMPH‑1, adults with obesity but without diabetes receiving weekly retatrutide 12 mg lost a mean 25% of baseline body weight by week 80 (phase 3; n=2,339), with gastrointestinal events common and ~11% discontinuations due to adverse events [1]. Among participants with knee osteoarthritis (n≈574), pain scores declined more than on placebo; in obstructive sleep apnea (n≈243), the apnea‑hypopnea index fell by more than 30 events per hour on retatrutide versus roughly 10 per hour on placebo, suggesting clinically meaningful improvement [1]. A two‑year extension cohort neared an average ~30% loss, although no head‑to‑head trial versus semaglutide or tirzepatide was conducted in this program [1].

Why it matters

  • U.S. payers—including Medicare Part D plans, state Medicaid programs, and self‑insured employers—tend to reimburse labeled outcomes they already manage, such as cardiovascular risk and obstructive sleep apnea; Wegovy’s 2024 FDA cardiovascular‑risk label enabled Part D coverage pathways, which retatrutide could emulate if it secures outcomes‑based indications [4][7].
  • Supply will gate share just as much as efficacy; Lilly’s announced $3.5B injectable/device facility in Lebanon County, Pennsylvania adds capacity on top of prior sites to reduce shortages that limited first‑wave GLP‑1 uptake in 2023–2024 [8].

Original analysis

Efficacy stack‑up (cross‑trial optics, not equivalence)

  • Retatrutide 12 mg: −25.0% at 80 weeks in TRIUMPH‑1; two‑year extension near ~30% in a subset [1].
  • Tirzepatide 15 mg (SURMOUNT‑1): −22.5% at 72 weeks in adults with obesity [3].
  • Semaglutide 2.4 mg (STEP 1): −14.9% at 68 weeks in adults with obesity/overweight [2].

Cross‑trial comparisons are imperfect, but the ordering is consistent: retatrutide > tirzepatide > semaglutide on average percentage loss at peak doses and similar durations [1][2][3]. TRIUMPH‑1’s added endpoints—apnea‑hypopnea index reduction and knee pain improvement—map to reimbursed services like sleep studies, PAP supplies, and orthopedic visits, which strengthens the coverage case beyond pounds lost [1].

— Back‑of‑envelope: revenue sizing with shown work
Goldman Sachs pegs 2030 anti‑obesity drug sales near $95B globally [6]. If Lilly holds 45% obesity share across its franchise by 2030 and retatrutide drives 25% of Lilly’s obesity revenue, implied annual sales are $95B × 0.45 × 0.25 = $10.69B (≈$10.7B) [6]. This scenario assumes Zepbound remains the volume leader while retatrutide captures the premium‑efficacy/outcomes tier.

— 2×2: “Efficacy × Coverage” positioning

  • High efficacy / Broad coverage: Targets outcomes‑labeled indications (e.g., OSA, CV risk) that Medicare Part D and commercial plans already cover; Zepbound holds an FDA OSA label from 2024, and Wegovy holds a 2024 CV‑risk label, establishing the playbook [5][4].
  • High efficacy / Narrow coverage: Likely starting point for retatrutide at launch if weight loss dominates the label without immediate outcomes endpoints [1].
  • Moderate efficacy / Broad coverage: Semaglutide’s CV‑risk label extends access to eligible Part D beneficiaries regardless of diabetes status [4].
  • Moderate efficacy / Narrow coverage: Where earlier‑stage competitors sit until they translate weight loss into claim‑linked outcomes and codes.

— Contrarian read
Consensus says “25–30% weight loss wins by itself,” but 2024–2026 payer behavior shows labels drive budgets: Wegovy scaled Part D access with its CV‑risk indication, and Zepbound unlocked an OSA path via FDA approval in 2024 [4][5]. Retatrutide’s outcomes signals look strong, yet broad reimbursement will hinge on the exact language that lands on the U.S. label and how quickly those endpoints are reflected in coverage policies [1][7]. Expect Lilly to prioritize outcomes submissions to convert trial endpoints into billable, code‑aligned reasons to pay.

— Named‑stakeholder breakdown

  • Eli Lilly and Company: Portfolio management is key; Lilly can segment Zepbound for volume and retatrutide for peak efficacy/outcomes while de‑risking supply through the $3.5B Pennsylvania site announced in 2024 [8].
  • Novo Nordisk: Wegovy’s 2024 FDA cardiovascular indication widened Medicare Part D doors, shaping price anchors and coverage precedents that any newcomer, including retatrutide, must meet or exceed [4].
  • Medicare Part D plans: CMS signaled in 2024 that FDA‑approved CV‑risk reduction with semaglutide is coverable under Part D, setting a template for outcomes‑labeled anti‑obesity medicines and influencing employer and Medicaid policies in 2025–2027 [7][4].

What others are missing

The pivotal angle is label architecture tied to billable outcomes, not another 2–5 percentage points of weight loss; Medicare’s 2024 acceptance of Wegovy’s CV‑risk indication for Part D, plus Zepbound’s 2024 OSA approval, show that coverage flows to conditions with existing codes and utilization management playbooks (AHI thresholds, CPAP claims, CV events) [4][5]. Retatrutide’s trial endpoints mirror those realities—apnea‑hypopnea reductions and osteoarthritis pain scores—so the gating item is whether Lilly wins explicit outcomes language on the U.S. label in time to influence 2027 benefit designs and formularies [1][7].

What to watch next

  1. By December 31, 2027, Lilly submits a U.S. application for retatrutide in obesity with at least one outcomes endpoint (OSA or OA) included in the filing package.
  2. By June 30, 2028, Lilly’s Lebanon County, Pennsylvania site reaches commercial production of GLP‑1/GIP/glucagon‑class injectables to support retatrutide or Zepbound scale‑up [8].
  3. By September 30, 2028, at least two top‑10 Medicare Part D plans publish coverage criteria that explicitly reference outcomes labels (OSA or CV risk) as primary gateways for anti‑obesity drug access [7][4][5].

My take

Retatrutide has reset the efficacy ceiling to roughly 25–30% average loss over 80–104 weeks in non‑diabetic adults, which is a clinical leap but not a coverage guarantee in the United States [1]. The next competitive phase favors drugs that combine high efficacy with outcomes‑based labels that plans already know how to reimburse, plus dependable supply chains that avoid the 2023–2024 shortages. Lilly looks positioned to run that playbook: Zepbound carries an OSA label from 2024, Wegovy has a CV‑risk precedent to match, and the Pennsylvania capacity expansion supports scale. The likely 2027–2029 strategy is portfolio lock‑in: Zepbound for broad, outcomes‑anchored access and retatrutide as the premium, outcomes‑rich sequel.

Sources

  1. Eli Lilly — TRIUMPH‑1 retatrutide topline (Phase 3) and key endpoints (https://investor.lilly.com/news-releases) — Primary efficacy figures (−25% at 80 weeks), discontinuations, and OA/OSA endpoint summaries used for the trial facts.

  2. New England Journal of Medicine — STEP 1: Once‑Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2032183) — Benchmark −14.9% at 68 weeks to contextualize legacy GLP‑1 efficacy.

  3. New England Journal of Medicine — SURMOUNT‑1: Tirzepatide in Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038) — Benchmark −22.5% at 72 weeks for tirzepatide to anchor cross‑trial optics.

  4. U.S. Food and Drug Administration — Wegovy cardiovascular‑risk reduction approval (2024) (https://www.fda.gov/news-events/press-announcements/) — Confirms a CV‑risk indication that Part D plans can and do cover.

  5. U.S. Food and Drug Administration — Zepbound obstructive sleep apnea approval (2024) (https://www.fda.gov/news-events/press-announcements/) — Establishes the first FDA‑approved medication for OSA in adults with obesity, a key outcomes precedent.

  6. Goldman Sachs — Anti‑obesity market outlook (~$95B by 2030) (https://www.goldmansachs.com/insights/) — Market sizing and price‑erosion context for the back‑of‑envelope revenue scenario.

  7. Centers for Medicare & Medicaid Services — Medicare Part D coverage communications for obesity drugs with outcomes labels (2024) (https://www.cms.gov/newsroom) — Clarifies how FDA‑labeled CV‑risk indications expand Part D coverage pathways.

  8. Eli Lilly — $3.5B Pennsylvania manufacturing site announcement (2024) (https://investor.lilly.com/news-releases) — Details on Lebanon County capacity build relevant to supply and launch readiness.



Related update: We recently published an article that expands on this topic: read the latest post.

AI Surge Sparks Power Grid Investment | Analysis by Brian Moineau

Posted on by Brian Moineau

Power stocks with AI tailwinds: why Goldman Sachs says the grid matters now

Goldman Sachs flags power infrastructure stocks poised to benefit from AI-driven demand and geopolitics — and that sentence should make investors sit up. The wave of AI capex is no longer just about chips and cloud software; it’s reshaping where and how electricity is produced, transmitted, and stored. If you follow markets, the idea that power companies are suddenly “AI plays” sounds odd — but the underlying math is simple: models need power, racks need cooling, and hyperscalers are spending at scale.

What Goldman Sachs is seeing and why it matters

Goldman’s research maps a fast-growing disconnect between compute demand and existing power infrastructure. Their analysis estimates large increases in data center power use and projects surging capital expenditures by hyperscalers to build AI-ready facilities and connect them to reliable supply. That translates into three concrete investment vectors:

  • Higher demand for generation capacity and dispatchable resources (gas, hydrogen-ready plants, and accelerated renewables plus firming).
  • Grid upgrades: transmission lines, substations, and interconnect capacity to move large blocks of power to hyperscale campuses.
  • Flexibility and reliability solutions: battery storage, microgrids, and resilience services sold to data centers and industrial consumers.

These are not abstract ideas. Goldman and others forecast data center power demand growing materially over the next several years, forcing utilities and independent power providers to respond — and creating revenue opportunities for companies that build or enable that infrastructure. (goldmansachs.com)

Geo-politics and the energy angle

Geopolitics complicates — and amplifies — the thesis. Countries and hyperscalers are wary of relying on single-region supply chains or fragile grids. That has two effects:

  • Onshoring and regional diversification of data centers, which boosts demand for local generation and transmission investment.
  • Strategic stockpiles and long-term contracts for firm power, which favor utilities and project developers that can deliver scale and contractual reliability.

In places where grid constraints or permitting slow projects, premium pricing and green-reliability solutions become possible. Goldman explicitly links national energy security concerns and the AI race: countries that secure power for AI hardware gain a strategic edge, and investors notice where that spending is likely to land. (finance.yahoo.com)

Winners and the kinds of stocks to watch

Not every company that touches “power” will benefit equally. The most direct beneficiaries tend to fall into a few categories:

  • Large utilities and transmission builders with permitting know-how and deep balance sheets.
  • Independent power producers and developers that can supply fast-build generation or long-term contracts.
  • Energy storage and grid-software firms that unlock capacity, enable demand response, or provide resiliency to hyperscalers.
  • Specialist contractors and equipment makers that build substations, switchgear, and data-center-adjacent microgrids.

Expect sector dispersion: some regulated utilities may see steady, regulated returns from interconnection work; merchant developers might capture outsized upside via long-term AI contracts. Goldman’s work highlights that investors should look past simple “data center” tickers and toward the power chain that supplies those facilities. (goldmansachs.com)

Risk checklist before you chase the trade

This isn’t a free lunch. Several risks can blunt the upside for “power stocks with AI tailwinds”:

  • Efficiency and architectural advances. If chip and system-level improvements reduce power per unit of compute faster than expected, demand could moderate.
  • Permitting and timeline risk. Transmission and large generation projects face long lead times and political pushback.
  • Commodity exposure. Some developers rely on natural gas prices or supply chains that can be volatile.
  • Crowd and valuation risk. The story has drawn attention; some stocks already price in a lot of future AI-driven revenue.

Assess whether a company’s near-term cash flows and balance sheet can survive potential delays. Tailwinds matter — but execution and timing matter more for shareholder returns.

Signals to monitor going forward

If you want to track whether this theme is real and sustainable, watch for these signals:

  • Announcements of hyperscaler long-term power purchase agreements (PPAs) or dedicated off-take deals.
  • Regulatory filings and interconnection queue moves that indicate transmission commitments.
  • Utility capex plans that explicitly add AI/data-center load or resilience programs.
  • Changes in grid stress metrics (peak occupancy rates, curtailments, connection backlogs).

These indicators separate PR headlines from committed, real-world spending. Goldman’s modeling also points to occupancy and utilization rates in data centers as a revealing metric — if occupancy stays near peak, structural power demand is more likely to persist. (goldmansachs.com)

Power stocks with AI tailwinds: a practical investor stance

If you’re building exposure, consider a thoughtful mix rather than one concentrated bet:

  • Core utility exposure for regulated, defensive income and steady capex recovery.
  • A satellite allocation to developers and storage specialists that can outperform on execution.
  • Avoid overpaying for momentum names that already assume the full narrative.

Rebalance toward companies with proven project pipelines, strong relationships with hyperscalers, or niche technologies that reduce integration risk. Time horizons matter — this is a multi-year structural story, not a lightning trade.

My take

The AI buzz has shifted the investment map. What began as a race for semiconductors and talent is morphing into an infrastructure buildout where electrons matter as much as exabytes. Goldman’s emphasis on power infrastructure is a useful reminder: durable secular themes often hide in pipes, wires, and contracts. For investors, the interesting opportunities are those that combine policy-facing scale, operational execution, and long-term contracted cash flows. Those are the companies most likely to convert AI demand into real returns. (goldmansachs.com)

Sources

Copper Collapse Looms as Iran Tensions | Analysis by Brian Moineau

Posted on by Brian Moineau

A fragile wire: Goldman Warns on Copper as Iran War Threatens Global Economy

Copper is a bellwether for the global economy — and now that bell is ringing with alarm. Goldman Warns on Copper as Iran War Threatens Global Economy was the blunt headline echoing through markets, and for good reason. With the Strait of Hormuz intermittently closed and diplomatic deadlines looming, traders, manufacturers and miners all face the possibility that copper’s recent wobble could turn into a sharper, more prolonged fall.

Why copper matters right now

Copper is everywhere: wiring, motors, renewable-energy systems, EVs and construction. Because it sits at the intersection of heavy industry and high-tech demand, its price moves reflect both supply-chain frictions and growth expectations.

Goldman Sachs warned that copper is vulnerable to further declines if the Strait of Hormuz remains blocked. The bank’s point is twofold: one, the immediate logistics shock — stranded shipments, strained alternative ports and rising freight and insurance costs — reduces physical availability in key consumption hubs; and two, the broader macro shock from higher energy prices and slower growth undercuts demand. Together, these forces can push prices down even as some supply-side inputs become costlier. (finance.yahoo.com)

The mechanics: how a Gulf chokepoint ripples through the copper chain

  • Disrupted shipping routes. The Strait of Hormuz handles a huge share of seaborne energy flows. Its closure forces rerouting and congests alternative ports such as Khor Fakkan and Fujairah, which are near capacity. That has stranded shipments of copper cathode and delayed deliveries. (fastmarkets.com)
  • Sulfuric acid shortages. Less obvious but crucial: Middle Eastern producers supply granulated sulfur — feedstock for sulfuric acid used in copper leaching and refining. Interruptions to those chemical flows can throttle smelters and refineries in Latin America and Africa, tightening refined copper availability even if ore output remains steady. (fastmarkets.com)
  • Demand shock from higher energy costs. Oil and gas volatility feeds directly into manufacturing costs. As energy costs spike and inflation persists, project owners delay construction and manufacturers scale back production — both of which reduce copper consumption. Goldman’s warning includes this growth-sapping channel. (bloomberg.com)

Goldman Warns on Copper as Iran War Threatens Global Economy — what the numbers say

Market reports and industry intelligence point to tangible flows at risk. Fastmarkets and other market sources noted roughly 40,000 tonnes per month of copper cathode that previously moved through Jebel Ali are now running into rerouting headaches. Meanwhile, LME prices have shown volatility: a swing down to multi‑month lows and sharp rebounds tied to political headlines and ceasefire talks. These are not just abstractions — they are monthly tonnages, port berthings and processing inputs that power factories. (fastmarkets.com)

A paradox: price down while supply tightens

This is where the story gets counterintuitive. Normally a physical squeeze lifts prices. But here, a growth shock (weaker demand because of economic uncertainty and expensive energy) collided with localized availability problems. That mix can push prices lower in futures markets as traders price weaker demand, even though certain regions face acute shortages and logistical bottlenecks. In short, a market can be physically tight in places and still trade lower on macro fears. (spglobal.com)

Broader implications for industries and investors

  • Manufacturers and contractors: Watch inventories and just-in-time exposure. Firms reliant on the Gulf for semi-finished copper or sulfuric acid need contingency plans.
  • Miners and smelters: Expect margins to be squeezed and short-term shut-ins if chemical inputs don’t arrive. Capital projects may be delayed, compounding future supply risk.
  • Traders and funds: Volatility will create trading opportunities but also higher collateral and margin pressure. Hedging becomes more expensive.
  • Policy and geopolitics: A prolonged reopening impasse would push central banks and governments to reassess inflation trajectories and growth forecasts, influencing interest rates and risk premia. (spglobal.com)

How markets reacted and what changed

In recent days news flow oscillated between threats and de-escalation. Reports indicate that U.S.-Iran ceasefire talks and pauses in strikes caused oil to tumble and risk assets to rally, which in turn nudged copper prices higher from some earlier lows. That demonstrates how quickly sentiment and physical risk can reprice base metals. Still, Goldman’s central caution remains: if the Hormuz disruption persists, copper is vulnerable to further price moves — potentially downward on demand fears or upward in localized spot tightness. (bloomberg.com)

Key takeaways

  • Copper sits at the intersection of logistics risk and macro demand; both channels are active because of the Iran war.
  • The Strait of Hormuz closure has immediate logistical effects (stranded cathode flows) and secondary industrial effects (sulfuric acid shortages).
  • Prices can fall even amid regional shortages if global growth expectations deteriorate.
  • Companies with supply-chain exposure and investors in base-metals need to reassess buffer inventories and hedging strategies.

My take

We’re witnessing a classic modern supply‑shock meets demand‑shock scenario. The near-term noise will remain headline-driven — each diplomatic volley or ceasefire pause will rattle prices. But the structural lesson is longer-lived: global manufacturing chains depend on chokepoints and specialized chemical inputs more than many realize. That fragility argues for diversified sourcing and clearer industry contingency plans, not just for copper but for any commodity where a handful of routes or inputs concentrate risk.

Markets will price headlines, but the physical world — ports, warehouses, smelters and acid plants — ultimately determines who feels the pain. Companies that treat copper’s current lull as a pause, not a permanent repricing, will be better placed when the next swing comes.

Sources



Related update: We recently published an article that expands on this topic: read the latest post.

Citi Joins Goldman in Asking Junior Bankers to Reveal If They Accepted Other Jobs – Bloomberg.com | Analysis by Brian Moineau

Posted on by Brian Moineau

Citi Joins Goldman in Asking Junior Bankers to Reveal If They Accepted Other Jobs - Bloomberg.com | Analysis by Brian Moineau

Title: The Tug of War for Junior Bankers: Citi and Goldman Sachs Draw a Line in the Sand

In a move reminiscent of a high-stakes poker game, Citigroup Inc. has decided to up the ante in the ongoing talent war within the financial sector. Joining the ranks of Goldman Sachs, Citi is now asking its new class of investment-banking analysts to come clean about any other job offers they've accepted from rival firms. This strategic maneuver aims to stem the aggressive recruitment efforts from private equity firms, which are increasingly luring bright young talent away from traditional banking roles.

The Great Talent Chase


The financial industry has always been known for its fierce competition—not just in the markets, but also in the recruitment of top talent. The allure of private equity has been especially potent in recent years, promising not only lucrative pay packages but also a more balanced lifestyle compared to the grueling hours of investment banking. It's no wonder that fresh-faced analysts, many of whom likely spent their college years pulling all-nighters, are tempted by the siren call of private equity.

Citi’s move, following Goldman Sachs' similar requirement, highlights the growing tension between banks and private equity firms. It’s akin to a chess match, with each side trying to outmaneuver the other. Yet, this isn't just about job offers; it's about the broader power dynamics within the industry. Banks are keen to retain their talent pool, especially as they navigate an increasingly complex global economy.

A Broader Context


This development comes at a time when the labor market across various sectors is experiencing seismic shifts. For instance, the tech industry has seen its own version of a talent tug-of-war, with startups and established giants vying for engineers skilled in AI and machine learning—fields that are, quite literally, shaping the future.

Moreover, the concept of employee loyalty is evolving. In today's gig economy, switching jobs frequently is no longer frowned upon but often seen as a strategic career move. This shift in mindset is not lost on the financial industry, where the traditional path of climbing the corporate ladder within a single organization is being challenged by more fluid career trajectories.

Navigating the New Normal


For new analysts entering the banking world, this scenario presents both a challenge and an opportunity. On one hand, they are under significant pressure to be transparent about their career intentions. On the other hand, they have more options than ever before, allowing them to craft a career that aligns with their personal and professional goals.

With Citi and Goldman Sachs leading the charge, it's likely that other banks will follow suit, adopting similar measures to protect their talent pipelines. However, it's crucial for these institutions to balance this with initiatives that genuinely enhance employee satisfaction and career development.

Final Thoughts


As the dust settles, one thing is clear: the financial sector is at a crossroads. The actions of Citi and Goldman Sachs are emblematic of a broader shift in how companies are approaching talent retention. It's not just about offering competitive salaries anymore; it's about creating environments where employees feel valued, challenged, and, most importantly, understood.

In the end, the real winners will be the organizations that successfully navigate this new landscape by fostering a culture of transparency, innovation, and respect. After all, in the game of chess—or poker, for that matter—it's not just about the pieces on the board but how you play the game.

Read more about AI in Business

Read more about Latest Sports Trends

Read more about Technology Innovations